Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
- Author(s)
- Beaumont, S; Harrison, S; Er, J;
- Details
- Publication Year 2021-09,Volume 13,Issue #17,Page 4479
- Journal Title
- Cancers
- Publication Type
- Research article
- Abstract
- Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.
- Department(s)
- Dental Oncology; Haematology
- PubMed ID
- 34503289
- Publisher's Version
- https://doi.org/10.3390/cancers13174479
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers13174479- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-30 08:01:47
Last Modified: 2025-05-30 08:02:20